Thread by @BullsforBears

@GranulesIndia
Q2fy21
Revenue up 22.7% to 858 crs
Formulations up 22.4% yoy 430 crs
API up 17% to 255
PFI up 32.6% to 173 crs
Vizag unit V commissioned for API ,oncology segment,
Company plans gradual shift from commoditized API to more complex drugs/ Formulations
#stocks

Company expects to commission MUPS block by Q3fy22
- Revenue contribution of core mols dropped to 70 from 80-85% end of Fy20
- #granules has 32 ANDA approved ,expect to launch 6 of these in Fy21
- Revised PAT guidance to 30% post Fy21 from 25% earlier
#StockMarket #Nifty

Company plans 7-9 product filings/year, atleast 5 for the US market
- Top 5 mols contributed 70%
- Capex guidance of 3.5 to 4 bn for fy21 & 3bn for Fy22
- Relaunch Metformin 750 mg in US over next year
- EU sales 23 % expected to reach 28% by Fy23, US sales to decline to 43%

Delayed launch of new drugs to ensure uninterrupted supply of existing mols
- Margin expansion 935 bps led higher sales of PFI & FD ,also better product mix
- Key risks include delayed in US product launches & adverse USFDA inspection
- New Vizag facility 100% functional fy22

Launched one new product through Granules pharma
- 4 ANDA approvals in Q2
-Expect to launch 3 to 5 products from GIL,GPI in h2fy21
- 1 product launch in EU in Q4 or Q1fy22
- MUPS block to come onstream Q3,1st product approval with 4 competitors from Gagillapur
@GranulesIndia

Company has 8 mftg facilities,7 in India ,1 in US
- API facilities at Bonthapally,Jeedimetla,Vizag
-Metformin API manufactured at Jeedimetla
- Vizag plant mfts API for oncology ,non-onco
- Gagillapur facility for PFI,FD
-Aim expand 8 API from Unit 4,5 to 28 by fy23 ,13 onco API

MUPS ( Multi unit pellet system) - pellets for oral release drugs resistant to gastric acid,facility to be integrated with Unit 5 in Vizag
Block to be operational by Q3fy22 ,produce 2.5 to 5b FDs/annum
Aim 13 products using MUPS

New Formulations drugs,Ramp up API to drive growth